Biohaven Pharmaceutical Holding Co Ltd (BHVN) Sees Significant Growth in Short Interest

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) saw a large growth in short interest in the month of December. As of December 29th, there was short interest totalling 1,196,544 shares, a growth of 38.4% from the December 15th total of 864,719 shares. Approximately 5.9% of the company’s stock are sold short. Based on an average trading volume of 289,382 shares, the short-interest ratio is presently 4.1 days.

In other Biohaven Pharmaceutical news, insider Robert Berman sold 160,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $25.76, for a total transaction of $4,121,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gregory Bailey sold 50,000 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $33.71, for a total transaction of $1,685,500.00. Following the transaction, the director now owns 2,516,701 shares in the company, valued at approximately $84,837,990.71. The disclosure for this sale can be found here. Insiders have sold a total of 983,608 shares of company stock worth $27,275,749 in the last quarter.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of Biohaven Pharmaceutical by 1.1% in the fourth quarter. BlackRock Inc. now owns 1,154,207 shares of the company’s stock valued at $31,139,000 after purchasing an additional 12,505 shares during the last quarter. Eagle Asset Management Inc. grew its position in Biohaven Pharmaceutical by 20.4% during the fourth quarter. Eagle Asset Management Inc. now owns 1,104,999 shares of the company’s stock valued at $30,207,000 after buying an additional 187,243 shares during the period. Candriam Luxembourg S.C.A. bought a new position in Biohaven Pharmaceutical during the fourth quarter valued at about $2,158,000. Swiss National Bank bought a new position in Biohaven Pharmaceutical during the fourth quarter valued at about $413,000. Finally, Emerald Advisers Inc. PA grew its position in Biohaven Pharmaceutical by 52.0% during the fourth quarter. Emerald Advisers Inc. PA now owns 369,782 shares of the company’s stock valued at $9,977,000 after buying an additional 126,455 shares during the period. Institutional investors own 47.76% of the company’s stock.

Shares of Biohaven Pharmaceutical (NYSE BHVN) traded down $0.69 during mid-day trading on Friday, hitting $29.71. 419,481 shares of the stock traded hands, compared to its average volume of 431,276. The stock has a market capitalization of $1,070.00 and a P/E ratio of -5.69. Biohaven Pharmaceutical has a 52 week low of $17.00 and a 52 week high of $39.51.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its earnings results on Tuesday, November 14th. The company reported ($1.19) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. analysts forecast that Biohaven Pharmaceutical will post -6.4 EPS for the current year.

Several research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Canaccord Genuity assumed coverage on shares of Biohaven Pharmaceutical in a report on Friday, December 15th. They set a “buy” rating and a $30.00 price objective on the stock. BidaskClub downgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, October 27th. Piper Jaffray Companies set a $48.00 price objective on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Monday, December 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of Biohaven Pharmaceutical in a report on Wednesday, November 15th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $36.14.

COPYRIGHT VIOLATION WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Sees Significant Growth in Short Interest” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://ledgergazette.com/2018/02/12/short-interest-in-biohaven-pharmaceutical-holding-co-ltd-bhvn-rises-by-38-4.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply